口服HCFU后肝癌患者血液及组织中HCFU与5-氟尿嘧啶水平
[HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU].
作者信息
Mori M, Hamazaki K, Mimura H, Orita K
机构信息
1st Dept. of Surgery, Okayama Medical University.
出版信息
Gan To Kagaku Ryoho. 1989 Dec;16(12):3763-8.
HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels. Blood and tissue 6-8 hr. after oral administration. The concentration of 5-FU in tissue was almost in the effective levels. In addition, the 5-FU level in the tissue of hepatocellular carcinoma tended to be higher than in non cancerous portion of the liver. 5-FU tissue concentration was not correlated with various laboratory data for the liver function (K-ICG, T. bil, GOT, GPT, etc.) From these results, it is suggested that HCFU is a useful anticancer agent for hepatocellular carcinoma especially for the cases accompanied liver cirrhosis.
对14例肝细胞癌患者（包括11例肝硬化患者）口服给予HCFU，并评估HCFU和5-氟尿嘧啶（5-FU）水平。口服给药后6-8小时采集血液和组织样本。组织中5-FU的浓度几乎处于有效水平。此外，肝细胞癌组织中的5-FU水平往往高于肝脏非癌部分。5-FU组织浓度与各种肝功能实验室数据（K-ICG、总胆红素、谷草转氨酶、谷丙转氨酶等）无关。从这些结果来看，提示HCFU是一种对肝细胞癌有用的抗癌药物，尤其适用于伴有肝硬化的病例。
Zotero 插件